Opportunities for using gonadotropin-releasing hormone agonist for luteal phase support in the in vitro fertilization program
Aim. To investigate the effectiveness of in vitro fertilization (IVF) programs in which the luteal phase support (LPS) was administered in the form of either a combined regimen of gonadotropin-releasing hormone agonist (GnRH-a) and micronized progesterone or the standard LPS regimen of micronized progesterone. Material and methods. The study comprised 207 patients under the age of 38 years with tubo-peritoneal, male, and mixed factor infertility. On the day of transvaginal puncture (TVP), the patients were randomized into two groups with different LPS regimens. In group 1 (n = 92) patients received natural micronized progesterone 600 mg/day given vaginally from day 1 after TVP and a single subcutaneous dose of 0.1 mg triptorelin on day 6 after the TVP. Patients in group 2 (n = 115) were administered vaginal natural micronized progesterone 600 mg/day alone from day 1 after TVP. Results. The patients managed with the combined LPS regimen had higher rates of implantation (30.6 and 16.6%, p <0.05), clinical pregnancy (40.2 and 26.9%, p = 0.04), progressive pregnancy (36.9 and 21.7%, p = 0.01), and live birth rates (31.5 and 19.1%, p = 0.04) compared with patients treated with the standard LPS regimen. Conclusion. Using the combined LPS regimen with GnRH-a has a positive effect on the IVF program outcomes in protocols with GnRH antagonists.Perminova S.G., Mityurina E.V., Savelyeva E.M.
Keywords
in vitro fertilization
GnRH-a
luteal phase support
micronized progesterone
References
1. Beckers N.G., Macklon N.S., Eijkemans M.J., Ludwig M., Felberbaum R.E., Diedrich K. et al. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. J. Clin. Endocrinol. Metab. 2003; 88(9): 4186-92.
2. Fatemi H.M. The luteal phase after 3 decades of IVF: what do we know? Reprod. Biomed. Online. 2009; 19(Suppl. 4): 4331.
3. Tesarik J., Hazout A., Mendoza-Tesarik R., Mendoza N., Mendoza C. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles. Hum. Reprod. 2006; 21(10): 2572-9.
4. Oliveira J.B., Baruffi R., Petersen C.G., Mauri A.L., Cavagna M., Franco J.G. Jr. Administration of single-dose GnRH agonist in the luteal phase in ICSI cycles: a meta-analysis. Reprod. Biol. Endocrinol. 2010; 8: 107.
5. Kyrou D., Kolibianakis E.M., Fatemi H.M., Tarlatzi T.B., Devroey P., Tarlatzis B.C. Increased live birth rates with GnRH agonist addition for luteal support in ICSI/IVF cycles: a systematic review and meta-analysis. Hum. Reprod. Update. 2011; 17(6 ): 734-40.
6. Van der Linden M., Buckingham K., Farquhar C., Kremer J.A., Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst. Rev. 2011; (10): CD009154.
7. Van der Linden M., Buckingham K., Farquhar C., Kremer J.A., Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst. Rev. 2015; (7): CD009154.
8. Fujii S., Sato S., Fukui A., Kimura H., Kasai G., Saito Y. Continuous administration of gonadotrophin-releasing hormone agonist during the luteal phase in IVF. Hum. Reprod. 2001; 16(8): 1671-5.
9. Qublan H., Amarin Z., Al-Quda M., Diab F., Nawasreh M., Malkawi S., Balawneh M. Luteal phase support with GnRH-a improves implantation and pregnancy rates in IVF cycles with endometrium of <or=7 mm on day of egg retrieval. Hum. Fertil. (Camb.). 2008; 11(1): 43-7.
10. Inamdar D.B., Majumdar A. Evaluation of the impact of gonadotropin-releasing hormone agonist as an adjuvant in luteal-phase support on IVF outcome. J. Hum. Reprod. Sci. 2012; 5(3): 279-84.
11. Isik A.Z., Caglar G.S., Sozen E., Akarsu C., Tuncay G., Ozbicer T., Vicdan K. Single-dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study. Reprod. Biomed. Online. 2009; 19(4): 472-7.
12. Martins W.P., Ferriani R.A., Navarro P.A., Nastri C.O. GnRH agonist during luteal phase in women undergoing assisted reproductive techniques: systematic review and meta-analysis of randomized controlled trials. Ultrasound Obstet. Gynecol. 2016; 47(2): 144-51.
13. Pirard C., Donnez J., Loumaye E. GnRH agonist as novel luteal support: results of a randomized, parallel group, feasibility study using intranasal administration of buserelin. Hum. Reprod. 2005; 20(7): 1798-804.
14. Klemmt P.A., Liu F., Carver J.G., Jones C., Brosi D., Adamson J. et al. Effects of gonadotrophin releasing hormone analogues on human endometrial stromal cells and embryo invasion in vitro. Hum. Reprod. 2009; 24(9): 2187-92.
15. Casañ E.M.,Raga F.,Polan M.L. GnRH mRNA and protein expression in human preimplantation embryos. Mol. Hum. Reprod. 1999; 5(3): 234-9.
16. Nam D.H., Lee S.H., Kim H.S., Lee G.S., Jeong Y.W., Kim S. et al. The role of gonadotropin-releasing hormone (GnRH) and its receptor in development of porcine preimplantation embryos derived from in vitro fertilization. Theriogenology. 2005; 63(1): 190-201.
17. Raga F., Casan E.M., Wen Y., Huang H.Y., Bonilla-Musoles F., Polan M. Independent regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-3 in human endometrial stromal cells by gonadotropin-releasing hormone: implications in early human implantation. J. Clin. Endocrinol. Metab. 1999; 84(2): 636-42.
18. Lin L., Roberts V.J., Yen S. Expression of human gonadotropin-releasing hormone receptor gene in the placenta and its functional relationship to human chorionic gonadotropin secretion. J. Clin. Endocrinol. Metab. 1995;80(2): 580-5.
19. Raga F., Casan E.M., Kruessel J.S., Wen Y., Huang H.Y., Nezhat C. et al. Quantitative gonadotropin-releasing hormone gene expression and immunohistochemical localization in human endometrium throughout the menstrual cycle. Biol. Reprod. 1998; 59(3): 661-9.
20. Zhang X., Bocca S., Franchi A., Anderson S., Kaur M., Bajic V.B., Oehninger S. Do GnRH analogues directly affect human endometrial epithelial cell gene expression? Mol. Hum. Reprod. 2010; 16(5): 347-60.
21. Ata B., Yakin K., Balaban B., Urman B. GnRH agonist protocol administration in the luteal phase in ICSI-ET cycles stimulated with the long GnRH agonist protocol: a randomized, controlled double blind study. Hum. Reprod. 2008; 23(3): 668-73.
22. Ata B., Urman B. Single dose GnRH agonist administration in the luteal phase of assisted reproduction cycles: is the effect dependent on the type of GnRH analogue used for pituitary suppression? Reprod. Biomed. Online. 2010; 20(1): 165-6.
23. Zafardoust S., Jeddi-Tehrani M., Akhondi M., Sadeghi M., Kamali K., Mokhtar S. et al. Effect of administration of single dose GnRH agonist in luteal phase on outcome of ICSI-ET cycles in women with previous history of IVF/ICSI failure: a randomized controlled trial. J. Reprod. Infertil. 2015;16(2): 96-101.
24. Isikoglu M., Ozgur K., Oehninger S. Extension of GnRH agonist through the luteal phase to improve the outcome of intracytoplasmic sperm injection. J. Reprod. Med. 2007; 52(7): 639-44.
25. Razieh D.F., Maryam A.R., Nasim T. Beneficial effect of luteal-phase gonadotropin-releasing hormone agonist administration on implantation rate after intracytoplasmic sperm injection. Taiwan. J. Obstet. Gynecol. 2009; 48(3): 245-8.
26. Bar-Hava I., Mizrachi Y., Karfunkel-Doron D., Omer Y., Sheena L., Carmon N., Ben-David G. Intranasal gonadotropin-releasing hormone agonist (GnRHa) for luteal-phase support following GnRHa triggering, a novel approach to avoid ovarian hyperstimulation syndrome in high responders. Fertil. Steril. 2016; 106(2): 330-3.
27. Bar Hava I.,Blueshtein M.,Ganer Herman H.,Omer Y.,Ben David G. Gonadotropin-releasing hormone analogue as sole luteal support in antagonist-based assisted reproductive technology cycles. Fertil. Steril. 2017;107(1): 130-5.
28. Kung H.F.,Chen M.J.,Guua H.F.,Chen Y.F.,Yi Y.C.,Yen-Ping Ho J., Chou M.M. Luteal phase support with decapeptyl improves pregnancy outcomes in intracytoplasmic sperm injection with higher basal follicle-stimulating hormone or lower mature oocytes. J. Chin. Med. Assoc.2014; 77(10): 524-30.
29. Marcus S.F., Ledger W.L. Efficacy and safety of long-acting GnRH agonists in in vitro fertilization and embryo transfer. Hum. Fertil. (Camb.). 2001; 4: 85-93.
30. Cachill D. Risks of GnRH agonist administration in early pregnancy. In: Filicory M., Flamigni C., eds. Ovulation induction: update ’98. London: Parthenon Publishing Group; 1998: 97-105.
31. Wilcox A.J., Weinberg C.R., O’Connor J.F., Baird D.D., Schlatterer J.P., Canfield R.E. et al. Incidence of early loss of pregnancy. N. Engl. J. Med. 1988; 319(4): 189-94.
32. Dolk H., Loane M., Garne E. The prevalence of congenital anomalies in Europe. Adv. Exp. Med. Biol. 2010; 686: 349-64.
33. Orvieto R., Kerner R., Krissi H., Ashkenazi J., Ben Rafael Z., Bar-Hava I. Comparison of leuprolide acetate and triptorelin in assisted reproductive technology cycles: a prospective, randomized study. Fertil. Steril. 2002; 78(6): 1268-71.
34. Ferring. Decapeptyl 0.1 mg. Available at: https://www.old.health.gov. il/units/pharmacy/trufot/alonim/DECAPEPTYL-dr_1382514091053.pdf Accessed September 29, 2016.
Received 26.02.2018
Accepted 02.03.2018
About the Authors
Perminova Svetlana Grigor’evna, Dr.Med.Sci., Leading Researcher at the Department of Gynecology #1, V.I. Kulakov NMRC for OG&P of Minzdrav of Russia.Address: 117997, Russia, Moscow, Academician Oparin St., 4. Tel.: 8 (916) 202-16-87. E-mail: perisvet@list.ru
Mityurina Elena Viktorovna, Ph.D., Physician at the Department of Gynecology #1, V.I. Kulakov NMRC for OG&P of Minzdrav of Russia.
Address: 117997, Russia, Moscow, Academician Oparin St., 4. Tel.: 8 (964) 796-74-65. E-mail: mity-elena@yandex.ru
Savelyeva Elena Maratovna, Ph.D. Student at the Department of Gynecology #1, V.I. Kulakov NMRC for OG&P of Minzdrav of Russia.
Address: 117997, Russia, Moscow, Academician Oparin St., 4. Tel.: 8 (925) 600-51-01. E-mail: elena-galliamova@rambler.ru
For citation: Perminova S.G., Mityurina E.V., Savelyeva E.M. Opportunities for using gonadotropin-releasing hormone agonist for luteal phase support in the in vitro fertilization program. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2018; (10): 72-9. (in Russian):
https://dx.doi.org/10.18565/aig.2018.10.72-79
Similar Articles
